June 10, 2021   |   by admin

The results of the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER; number. Editorial from The New England Journal of Medicine — JUPITER Clinical Directions — Polling Results. Authors & Reviewers · Submit a Manuscript · Subscribers · Institutions · Media · Advertisers · Agents · Permissions · Reprints · NEJM Career.

Author: Dougor Kazralabar
Country: Dominica
Language: English (Spanish)
Genre: Science
Published (Last): 26 August 2004
Pages: 343
PDF File Size: 11.67 Mb
ePub File Size: 7.47 Mb
ISBN: 365-3-12724-533-5
Downloads: 84192
Price: Free* [*Free Regsitration Required]
Uploader: Maran

Consistent effects were observed in all subgroups evaluated. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment.

Cleve Clin J Med. Michel de Lorgeril, et al. Results, Controversies, and Implications for Prevention”.

JUPITER trial – Wikipedia

Retrieved July 1, From Wikipedia, the free encyclopedia. N Engl J Med. Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. The trial was stopped early, after just 1. The article’s authors critiqued what they saw as flaws in the trial, pointing out that the cardiovascular mortality rate jupkter the case-fatality rate for myocardial infarction were much lower than they expected.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Comment in Ann Intern Med. Retrieved from ” https: The trial analyzed 17, patients without evidence of heart jjpiter but with high CRP levels. This page was last edited on 4 Novemberat The rates of the primary end point were 0. An I ntervention T rial E valuating R osuvastatin trial was a clinical jupifer aimed at evaluating whether statins reduce heart attacks and strokes in people with normal cholesterol levels.


Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.

On the role of C-reactive protein, a study employing Mendelian randomizationpublished in the Journal of the American Medical Association suggested that CRP does not play a causal role in cardiovascular disease; the results may argue against CRP’s use as a marker of cardiovascular disease risk or for identifying subjects for statin therapy as in JUPITER, and more strongly argue against using CRP as a therapeutic target per se.

The trial was stopped after a njem follow-up of 1. Cardiovascular Quality and Outcomes.

They concluded that, “The results of the trial do not support the use of statin treatment for primary prevention of cardiovascular diseases and raise troubling questions concerning the role of commercial sponsors. By using this site, you agree to the Terms of Use and Privacy Policy.


Am J Kidney Uupiter. They also raised concerns about conflict of interest in the trial design and leadership: JUPITER was a randomized double-blind placebo-controlled study investigating the use of rosuvastatin in the primary prevention of cardiovascular disease.

The rosuvastatin group did not have a significant increase in myopathy or cancer but did have a nejmm incidence of physician-reported diabetes. Because half of all vascular events occur in patients with normal or low levels of LDL cholesterol, JUPITER was designed to determine whether hs-CRP testing could identify these patients, and whether statin therapy could prevent cardiovascular events among them.


Compared to patients taking a placebopatients given rosuvastatin had reductions in LDL and CRP levels, and a reduction of 0. Views Read Edit View history. Clinical trials related to cardiology Clinical trials sponsored by AstraZeneca Statins. Inresults presented at the American Heart Association meeting and published in the New England Journal of Medicine found that patients with low-to-normal LDL cholesterol receiving rosuvastatin had a lower rate of major cardiovascular events.

The trial was sponsored by AstraZenecathe marketer of Crestor rosuvastatin. There were no significant differences between the treatment groups with respect jejm muscle pain, muscle weakness, hepatic function, or renal function; however, the researchers noted small but statistically significant increases in mupiter rate of physician-reported diabetes and glycated hemoglobin values in the rosuvastatin group, an effect that has also been seen in studies with other jupitsr.

We randomly assigned 17, apparently healthy men and women with low-density lipoprotein LDL cholesterol levels of less than mg per deciliter 3. The trial focused on patients with normal low-density lipoprotein LDL cholesterol levels but increased levels of high-sensitivity C-reactive protein hs-CRP.